| 摘要 |
#CMT# #/CMT# Use of pharmaceutical formulations for the treatment of pathological vascular calcification occurring in renal disease, where the pharmaceutical formulation contains trimagnesium dicitrate and/or trimagnesium diisocitrate as an active agent, and the active agents are formed as a hydrate or anhydrate, is claimed. #CMT#ACTIVITY : #/CMT# Metabolic. #CMT#MECHANISM OF ACTION : #/CMT# None given. #CMT#USE : #/CMT# The formulation is useful: for treating/preventing pathological vascular calcification occurring in renal disease; in therapeutic treatment of pathological shifts in the calcium-phosphate product; and in hemodialysis and peritoneal dialysis; and in medical field in human being and veterinary field (all claimed). No biological data given. #CMT#ADVANTAGE : #/CMT# The formulation is free of calcium and phosphate compounds. #CMT#ORGANIC CHEMISTRY : #/CMT# Preferred Components: The trimagnesium dicitrate is a pentahydrate. The trimagnesium diisocitrate is undecahydrate. #CMT#PHARMACEUTICALS : #/CMT# Preferred Components: The active agents are present as a magnesium-potassium citrate salt. The active agents are present in combination with one or more B-complex vitamins. #CMT#ADMINISTRATION : #/CMT# Administration of the formulation is via infusion or injection in the form of tablets, effervescent tablets, chewable tablets, capsules, pills, powders, effervescent powders, granules, solutions, emulsions or suspensions (claimed). Administration of the formulation is oral. No dosage details given. |
